RayKnowChina Research Map
Shortlist0

RecruitingNasopharyngeal carcinomaPhase 3

Registered title, quoted from ClinicalTrials.gov

Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma

An open trial on nasopharyngeal carcinoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 5 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 5

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteFifth Affiliated Hospital of Sun Yat-sen University中山大学附属第五医院ZhuhaiHospital page
  2. Study siteSun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page
  3. Study siteWuzhou Red Cross Hospital梧州市红十字会医院WuzhouHospital page
  4. Study siteYuebei People's Hospital粤北人民医院ShaoguanHospital page
  5. Study siteZhongshan City People's Hospital中山市人民医院ZhongshanHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT04453813, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 9

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (9 points)Hide the checklist
  1. 18 years to 70 years; sex: all

    Registered eligibility fields

  2. Histologically confirmed recurrent nasopharyngeal carcinoma.

    Inclusion criterion 1

  3. Tumor staged as rT2-4N0-3M0,rII-IVa (according to the 8th AJCC edition).

    Inclusion criterion 3

    Resectable nasopharyngeal diseases: rT2 (the tumour is confined in the superficial parapharyngeal spacer and is more than 0.5cm from the internal carotid artery) and rT3 (the tumour is confined in the base wall of the sphenoid sinus and is more than 0.5cm from the internal carotid artery and cavernous sinus).

    Exclusion criterion 1

  4. The recurrence time is more than 12 months from the end of the first course of radiotherapy.

    Inclusion criterion 2

    Received a systematic glucocorticoid therapy within 4 weeks of the first dose of study medication.

    Exclusion criterion 8

    Prior therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) or CTLA-4 agent.

    Exclusion criterion 10

  5. Karnofsky scale (KPS)≥70.

    Inclusion criterion 5

  6. total bilirubin, AST and ALT levels of no more than 2.5 times the upper normal limit;

    Inclusion criterion 8

    creatinine clearance rate of at least 60 mL/min or creatinine of no more than 1.5 times the upper normal limit.

    Inclusion criterion 9

  7. Subjects must have a measurable disease by CT or MRI per RECIST 1.1 criteria.

    Inclusion criterion 4

  8. Has a known history of active TB (bacillus tuberculosis) within 1 year; patients with adequately treated active TB with 1 year.

    Exclusion criterion 9

    Has a known history of human immunodeficiency virus (HIV).

    Exclusion criterion 12

    Has hepatitis B surface antigen (HBsAg) positive with HBV DNA copy number of ≥1000cps/ml or hepatitis C virus (HCV) antibody positive

    Exclusion criterion 13

  9. Pregnancy or breast feeding

    Exclusion criterion 15

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT04453813, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Histologically confirmed recurrent nasopharyngeal carcinoma.
  • The recurrence time is more than 12 months from the end of the first course of radiotherapy.
  • Tumor staged as rT2-4N0-3M0,rII-IVa (according to the 8th AJCC edition).
  • Subjects must have a measurable disease by CT or MRI per RECIST 1.1 criteria.
  • Karnofsky scale (KPS)≥70.
  • Normal bone marrow function.
  • Normal liver and kidney function:
  • total bilirubin, AST and ALT levels of no more than 2.5 times the upper normal limit;
  • creatinine clearance rate of at least 60 mL/min or creatinine of no more than 1.5 times the upper normal limit.
  • Given written informed consent.

Exclusion Criteria:

  • Resectable nasopharyngeal diseases: rT2 (the tumour is confined in the superficial parapharyngeal spacer and is more than 0.5cm from the internal carotid artery) and rT3 (the tumour is confined in the base wall of the sphenoid sinus and is more than 0.5cm from the internal carotid artery and cavernous sinus).
  • The patients are suffering from severe nasopharyngeal necrosis, radiation induced brain injury, and fibrosis of the neck et. al, who are evaluated as unsuitable for secondary radiotherapy by the researchers.
  • Has known allergy to large molecule protein products or any compound of study therapy.
  • Has known subjects with other malignant tumors.
  • Has any active autoimmune disease or history of autoimmune disease.
  • Has a history of psychiatric substance abuse, alcoholism, or drug addiction.
  • The laboratory examination value does not meet the relevant standards within 7 days before enrollment
  • Received a systematic glucocorticoid therapy within 4 weeks of the first dose of study medication.
  • Has a known history of active TB (bacillus tuberculosis) within 1 year; patients with adequately treated active TB with 1 year.
  • Prior therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) or CTLA-4 agent.
  • Has active autoimmune disease (e.g., uveitis, enteritis, hepatitis, hypophysitis, nephritis, vasculitis, hyperthyroidism, and asthma requiring bronchodilator therapy). Patients with skin disease that doesn't require systemic treatment (e.g., vitiligo, psoriasis, or alopecia) will be allowed to enroll.
  • Has a known history of human immunodeficiency virus (HIV).
  • Has hepatitis B surface antigen (HBsAg) positive with HBV DNA copy number of ≥1000cps/ml or hepatitis C virus (HCV) antibody positive
  • Has received a live vaccine within 4 weeks of planned start of study therapy
  • Pregnancy or breast feeding

Quoted from ClinicalTrials.gov, NCT04453813, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT04453813, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT04453813